PL1648502T3 - Szczepionki przeciwko HCV - Google Patents

Szczepionki przeciwko HCV

Info

Publication number
PL1648502T3
PL1648502T3 PL04763141T PL04763141T PL1648502T3 PL 1648502 T3 PL1648502 T3 PL 1648502T3 PL 04763141 T PL04763141 T PL 04763141T PL 04763141 T PL04763141 T PL 04763141T PL 1648502 T3 PL1648502 T3 PL 1648502T3
Authority
PL
Poland
Prior art keywords
epitope
hcv
hcv vaccines
hotspot
vlcecydag
Prior art date
Application number
PL04763141T
Other languages
English (en)
Inventor
Michael Buschle
Jürgen Frisch
Christoph Klade
Karen Lingnau
Wolfgang Zauner
Gerd Zettlmeissl
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Publication of PL1648502T3 publication Critical patent/PL1648502T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL04763141T 2003-07-11 2004-07-09 Szczepionki przeciwko HCV PL1648502T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03450171 2003-07-11
EP04450062 2004-03-12
EP04763141A EP1648502B1 (en) 2003-07-11 2004-07-09 Hcv vaccines
PCT/EP2004/007540 WO2005004910A2 (en) 2003-07-11 2004-07-09 Hcv vaccines

Publications (1)

Publication Number Publication Date
PL1648502T3 true PL1648502T3 (pl) 2011-05-31

Family

ID=34066530

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04763141T PL1648502T3 (pl) 2003-07-11 2004-07-09 Szczepionki przeciwko HCV

Country Status (11)

Country Link
US (3) US20070031446A1 (pl)
EP (2) EP1648502B1 (pl)
JP (2) JP4734241B2 (pl)
CN (1) CN1822856B (pl)
AT (1) ATE489967T1 (pl)
AU (1) AU2004255456B2 (pl)
CA (1) CA2530062A1 (pl)
DE (1) DE602004030343D1 (pl)
PL (1) PL1648502T3 (pl)
TW (1) TWI358301B (pl)
WO (1) WO2005004910A2 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
NZ540098A (en) 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
CA2530062A1 (en) * 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
EP1722819B1 (en) * 2004-03-12 2007-12-26 Intercell AG Method for solubilising peptide mixtures
WO2006045677A1 (en) * 2004-10-29 2006-05-04 Intercell Ag Hcv vaccines for chronic hcv patients
AU2006226192A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
CA2645832A1 (en) * 2006-04-25 2007-11-01 Intercell Ag Hcv vaccinations
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
US20110217265A1 (en) * 2008-09-23 2011-09-08 Glenn Jeffrey S Screening for Inhibitors of HCV Amphipathic Helix (AH) Function
WO2010054446A1 (en) * 2008-11-11 2010-05-20 Ademovic Zlatko Combination of two or more peptides in a single stable lyophilized pharmaceutical compound
CN102378914B (zh) * 2009-03-30 2014-12-10 生物梅里埃公司 用于hcv检测的固体支持物
US20100322943A1 (en) 2009-06-17 2010-12-23 Thomas Cantor Therapeutic and diagnostic affinity purified specific polyclonal antibodies
EP2484378A4 (en) 2009-09-30 2013-05-22 Toray Industries HEPATITIS C VIRUS VACCINE COMPOSITION
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
US9752494B2 (en) 2013-03-15 2017-09-05 Kohler Co. Noise suppression systems
WO2016176330A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
US11596679B2 (en) * 2017-04-27 2023-03-07 Vanderbilt University Hepatitis C virus gene sequences and methods of use therefor
CN109212220B (zh) * 2018-09-21 2021-06-29 北京凯因科技股份有限公司 丙型肝炎病毒抗体快速检测试纸条
CA3178344A1 (en) 2020-03-31 2021-10-07 The Trustees Of The University Of Pennsylvania Universal influenza vaccine using nucleoside-modified mrna

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
DE3834729A1 (de) * 1988-10-12 1990-04-19 Behringwerke Ag Verwendung von zink-oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
ATE346302T1 (de) 1990-08-25 2006-12-15 Bioprocess Pty Ltd Nicht-a, nicht-b hepatitis virus antigen, und diagnostische verfahren.
KR0185426B1 (ko) 1991-06-24 1999-04-01 로버트 피. 블랙버언 씨형 간염 바이러스 폴리펩티드
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US20030152580A1 (en) * 1994-07-21 2003-08-14 Alessandro Sette Hla binding peptides and their uses
US5333965A (en) 1992-01-31 1994-08-02 Mailey John W In situ modular fastening system
SG49008A1 (en) 1993-03-05 1998-05-18 Cytel Corp Hla-a2.1 binding peptides and their uses
US6762024B2 (en) 1993-04-27 2004-07-13 Innogenetics, S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
DE69517521T2 (de) 1994-04-08 2001-03-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t-lymphocyten und die diagnose des hcv-kontaktes
AUPM543894A0 (en) * 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
CA2289040A1 (en) * 1997-05-01 1998-11-05 Protechtion Unlimited, Inc. Nerve growth factor as a vaccine adjuvant
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
AU5776799A (en) 1998-08-21 2000-03-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Modified hcv peptide vaccines
JP2003509465A (ja) * 1999-07-19 2003-03-11 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｃ型肝炎ウイルスに対する細胞性免疫応答の誘導
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
US20090130135A1 (en) * 1999-10-01 2009-05-21 Michael Buschle Hcv vaccines
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
EP1272215B1 (en) 2000-04-14 2007-10-10 Intercell AG Pharmaceutical preparations comprising modified peptides
HU228264B1 (en) * 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AU2001289813B2 (en) 2000-08-17 2005-07-28 Intercell Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US6588670B2 (en) * 2001-10-30 2003-07-08 Symbol Technologies, Inc. Medical diagnostic monitoring
US20050250716A1 (en) * 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
FR2843115B1 (fr) * 2002-08-02 2007-11-09 Commissariat Energie Atomique Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications
EP1537418A2 (en) 2002-09-13 2005-06-08 Intercell AG Method for isolating hepatitis c virus peptides
AU2004224746B2 (en) * 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
CA2530062A1 (en) * 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
WO2006045677A1 (en) * 2004-10-29 2006-05-04 Intercell Ag Hcv vaccines for chronic hcv patients

Also Published As

Publication number Publication date
US20110300170A1 (en) 2011-12-08
CA2530062A1 (en) 2005-01-20
WO2005004910A2 (en) 2005-01-20
EP2275131A3 (en) 2012-01-25
TWI358301B (en) 2012-02-21
EP1648502A2 (en) 2006-04-26
TW200503752A (en) 2005-02-01
EP1648502B1 (en) 2010-12-01
EP2275131A2 (en) 2011-01-19
DE602004030343D1 (de) 2011-01-13
JP2009513542A (ja) 2009-04-02
ATE489967T1 (de) 2010-12-15
WO2005004910A3 (en) 2005-04-21
JP2011088916A (ja) 2011-05-06
CN1822856B (zh) 2010-04-28
CN1822856A (zh) 2006-08-23
JP4734241B2 (ja) 2011-07-27
AU2004255456B2 (en) 2010-06-24
US20090155294A1 (en) 2009-06-18
AU2004255456A1 (en) 2005-01-20
US20070031446A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
TW200503752A (en) HCV vaccines
WO2001098333A3 (en) Modification of hepatitis b core antigen
AU5562798A (en) Recombinant live avian vaccine, using as vector the avian infectious laryngotracheitis virus.
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
FI894580L (fi) Non-a, non-b -hepatitisvirusantigenpeptid.
MA24458A1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire.
DK0725824T3 (da) Immunodominante humane T-celleepitoper af hepatitis C virus
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
DE69830579D1 (de) Chimäre impfstoffe gegen flaviviren
AU3448797A (en) Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus
IS7830A (is) Bóluefni gegn lifrarbólgu C veiru (HCV)
WO2001037869A9 (en) Vaccine compositions
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
AU2001290178A1 (en) A hepatitis c virus non-structural ns3/4a fusion gene
AU2001246331A1 (en) Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof
WO1997040147A8 (en) Antigenically reactive regions of the hepatitis a virus polyprotein
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
WO2007121491A8 (en) Hcv vaccinations
PT1194450E (pt) Vacina inactivada contra a calicivirose felina
AU2000252449A1 (en) Recombinant vaccines against infectious bursal disease virus
ATE409705T1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
MXPA01006919A (es) Una vacuna de virus de enfermedad bursal infecciosa de amplio espectro.
CA2072982A1 (en) Hepatitis a vaccines
WO2003084988A3 (de) Cd4+ t-lymphozyten spezifische hepatitis c virus-epitope
AU2002314610A1 (en) Attenuated very virulent infectious bursal disease virus